1
|
Pennati F, Belenkov S, Buccardi M, Ferrini E, Sverzellati N, Villetti G, Aliverti A, Stellari FF. Multiphase micro-computed tomography reconstructions provide dynamic respiratory function in a mouse lung fibrosis model. iScience 2024; 27:109262. [PMID: 38433926 PMCID: PMC10907835 DOI: 10.1016/j.isci.2024.109262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Revised: 12/13/2023] [Accepted: 02/14/2024] [Indexed: 03/05/2024] Open
Abstract
Micro-computed tomography derived functional biomarkers used in lung disease research can significantly complement end-stage histomorphometric measures while also allowing for longitudinal studies. However, no approach for visualizing lung dynamics across a full respiratory cycle has yet been described. Using bleomycin-induced lung fibrosis and the antifibrotic drug nintedanib as a test model, we implemented a four-dimensional (4D) micro-CT imaging approach consisting of 30 reconstructed volumes per respiratory cycle, coupled with deep-learning-assisted segmentation of lung volumes. 4D micro-CT provided an accurate description of inhalatory and exhalatory lung dynamics under resting conditions and revealed an inflammation-related obstructive pattern at day 7, followed by a restrictive pattern associated with fibrosis development at day 21. A milder restriction and fibrotic pathology resulted from nintedanib treatment. The similarity of 4D micro-CT data with those produced by diagnostic measurements, also points to its great potential as an exploratory tool for the discovery of clinically relevant therapeutic compounds.
Collapse
Affiliation(s)
- Francesca Pennati
- Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, Italy
| | | | - Martina Buccardi
- Department of Mathematical, Physical and Computer Sciences, University of Parma, Parma, Italy
| | - Erica Ferrini
- Department of Veterinary Science, University of Parma, Parma, Italy
| | | | - Gino Villetti
- Pharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, Italy
| | - Andrea Aliverti
- Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, Italy
| | - Franco Fabio Stellari
- Pharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, Italy
| |
Collapse
|
2
|
Stellari FF, Sala A, Ruscitti F, Buccellati C, Allen A, Risé P, Civelli M, Villetti G. CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice. Front Pharmacol 2019; 10:1337. [PMID: 31798449 PMCID: PMC6863066 DOI: 10.3389/fphar.2019.01337] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Accepted: 10/18/2019] [Indexed: 12/15/2022] Open
Abstract
Inhibitors of phosphodiesterase 4 (PDE4) are potent anti-inflammatory agents, inhibiting the production of inflammatory mediators through the elevation of intracellular cAMP concentrations. We studied the activity of a novel PDE4 inhibitor, CHF6001, both in vitro in human cells and in vivo, using bioluminescence imaging (BLI) in mice lung inflammation. Mice transiently transfected with the luciferase gene under the control of an NF-κB responsive element (NF-κB-luc) have been used to assess the in vivo anti-inflammatory activity of CHF6001 in lipopolysaccharide (LPS)-induced lung inflammation. BLI as well as inflammatory cells and the concentrations of pro-inflammatory cytokines were monitored in bronchoalveolar lavage fluids (BALF) while testing in vitro its ability to affect the production of leukotriene B4 (LTB4), measured by LC/MS/MS, by LPS/LPS/N-formyl--methionyl--leucyl-phenylalanine (fMLP)-activated human blood. CHF6001 inhibited the production of LTB4 in LPS/fMLP-activated human blood at sub-nanomolar concentrations. LPS-induced an increase of BLI signal in NF-κB-luc mice, and CHF6001 administered by dry powder inhalation decreased in parallel luciferase signal, cell airway infiltration, and pro-inflammatory cytokine concentrations in BALF. The results obtained provide in vitro and in vivo evidence of the anti-inflammatory activity of the potent PDE4 inhibitor CHF6001, showing that with a topical administration that closely mimics inhalation in humans, it efficiently disrupts the NF-κB activation associated with LPS challenge, an effect that may be relevant for the prevention of exacerbation episodes in chronic obstructive pulmonary disease subjects.
Collapse
Affiliation(s)
- Fabio F Stellari
- Pharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy
| | - Angelo Sala
- Department of Pharmaceutical Sciences, School of Drug Sciences, University of Milan, Milan, Italy.,IBIM, Consiglio Nazionale delle Ricerche, Palermo, Italy
| | - Francesca Ruscitti
- Pharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy
| | - Carola Buccellati
- Department of Pharmaceutical Sciences, School of Drug Sciences, University of Milan, Milan, Italy
| | - Andrew Allen
- Pharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy
| | - Patrizia Risé
- Department of Pharmaceutical Sciences, School of Drug Sciences, University of Milan, Milan, Italy
| | - Maurizio Civelli
- Pharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy
| | - Gino Villetti
- Pharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A, Parma, Italy
| |
Collapse
|
3
|
Ruscitti F, Ravanetti F, Donofrio G, Ridwan Y, van Heijningen P, Essers J, Villetti G, Cacchioli A, Vos W, Stellari FF. A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice. J Vis Exp 2018. [PMID: 29708527 DOI: 10.3791/56443] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by the progressive and irreversible destruction of lung architecture, which causes significant deterioration in lung function and subsequent death from respiratory failure. The pathogenesis of IPF in experimental animal models has been induced by bleomycin administration. In this study, we investigate an IPF-like mouse model induced by a double intratracheal bleomycin instillation. Standard histological assessments used for studying lung fibrosis are invasive terminal procedures. The goal of this work is to monitor lung fibrosis through noninvasive imaging techniques such as Fluorescent Molecular Tomography (FMT) and Micro-CT. These two technologies validated with histology findings could represent a revolutionary functional approach for real time non-invasive monitoring of IPF disease severity and progression. The fusion of different approaches represents a step further for understanding the IPF disease, where the molecular events occurring in a pathological condition can be observed with FMT and the subsequent anatomical changes can be monitored by Micro-CT.
Collapse
Affiliation(s)
| | | | | | | | | | - Jeroen Essers
- Department of Molecular Genetics, Vascular Surgery, Radiation Oncology, Erasmus MC
| | - Gino Villetti
- Corporate Preclinical R&D, Chiesi Farmaceutici S.p.A
| | | | | | | |
Collapse
|
4
|
Stellari FF, Ruscitti F, Pompilio D, Ravanetti F, Tebaldi G, Macchi F, Verna AE, Villetti G, Donofrio G. Heterologous Matrix Metalloproteinase Gene Promoter Activity Allows In Vivo Real-time Imaging of Bleomycin-Induced Lung Fibrosis in Transiently Transgenized Mice. Front Immunol 2017; 8:199. [PMID: 28298912 PMCID: PMC5331072 DOI: 10.3389/fimmu.2017.00199] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2016] [Accepted: 02/10/2017] [Indexed: 12/14/2022] Open
Abstract
Idiopathic pulmonary fibrosis is a very common interstitial lung disease derived from chronic inflammatory insults, characterized by massive scar tissue deposition that causes the progressive loss of lung function and subsequent death for respiratory failure. Bleomycin is used as the standard agent to induce experimental pulmonary fibrosis in animal models for the study of its pathogenesis. However, to visualize the establishment of lung fibrosis after treatment, the animal sacrifice is necessary. Thus, the aim of this study was to avoid this limitation by using an innovative approach based on a double bleomycin treatment protocol, along with the in vivo images analysis of bleomycin-treated mice. A reporter gene construct, containing the luciferase open reading frame under the matrix metalloproteinase-1 promoter control region, was tested on double bleomycin-treated mice to investigate, in real time, the correlation between bleomycin treatment, inflammation, tissue remodeling and fibrosis. Bioluminescence emitted by the lungs of bleomycin-treated mice, corroborated by fluorescent molecular tomography, successfully allowed real time monitoring of fibrosis establishment. The reporter gene technology experienced in this work could represent an advanced functional approach for real time non-invasive assessment of disease evolution during therapy, in a reliable and translational living animal model.
Collapse
Affiliation(s)
| | | | - Daniela Pompilio
- Chiesi Farmaceutici S.p.A., Corporate Pre-Clinical R&D, Parma, Italy; Dipartimento di Scienze Medico Veterinarie, Università di Parma, Parma, Italy
| | - Francesca Ravanetti
- Dipartimento di Scienze Medico Veterinarie, Università di Parma , Parma , Italy
| | - Giulia Tebaldi
- Dipartimento di Scienze Medico Veterinarie, Università di Parma , Parma , Italy
| | - Francesca Macchi
- Dipartimento di Scienze Medico Veterinarie, Università di Parma , Parma , Italy
| | | | - Gino Villetti
- Chiesi Farmaceutici S.p.A., Corporate Pre-Clinical R&D , Parma , Italy
| | - Gaetano Donofrio
- Dipartimento di Scienze Medico Veterinarie, Università di Parma , Parma , Italy
| |
Collapse
|
5
|
Stellari F, Bergamini G, Ruscitti F, Sandri A, Ravanetti F, Donofrio G, Boschi F, Villetti G, Sorio C, Assael BM, Melotti P, Lleo MM. In vivo monitoring of lung inflammation in CFTR-deficient mice. J Transl Med 2016; 14:226. [PMID: 27468800 PMCID: PMC4964274 DOI: 10.1186/s12967-016-0976-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Accepted: 07/13/2016] [Indexed: 12/14/2022] Open
Abstract
Background Experimentally, lung inflammation in laboratory animals is usually detected by the presence of inflammatory markers, such as immune cells and cytokines, in the bronchoalveolar lavage fluid (BALF) of sacrificed animals. This method, although extensively used, is time, money and animal life consuming, especially when applied to genetically modified animals. Thus a new and more convenient approach, based on in vivo imaging analysis, has been set up to evaluate the inflammatory response in the lung of CFTR-deficient (CF) mice, a murine model of cystic fibrosis. Methods Wild type (WT) and CF mice were stimulated with P. aeruginosa LPS, TNF-alpha and culture supernatant derived from P. aeruginosa (strain VR1). Lung inflammation was detected by measuring bioluminescence in vivo in mice transiently transgenized with a luciferase reporter gene under the control of a bovine IL-8 gene promoter. Results Differences in bioluminescence (BLI) signal were revealed by comparing the two types of mice after intratracheal challenge with pro-inflammatory stimuli. BLI increased at 4 h after stimulation with TNF-alpha and at 24 h after administration of LPS and VR1 supernatant in CF mice with respect to untreated animals. The BLI signal was significantly more intense and lasted for longer times in CF animals when compared to WT mice. Analysis of BALF markers: leukocytes, cytokines and histology revealed no significant differences between CF and WT mice. Conclusions In vivo gene delivery technology and non-invasive bioluminescent imaging has been successfully adapted to CFTR-deficient mice. Activation of bIL-8 transgene promoter can be monitored by non-invasive BLI imaging in the lung of the same animal and compared longitudinally in both CF or WT mice, after challenge with pro-inflammatory stimuli. The combination of these technologies and the use of CF mice offer the unique opportunity of evaluating the impact of therapies aimed to control inflammation in a CF background. Electronic supplementary material The online version of this article (doi:10.1186/s12967-016-0976-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Fabio Stellari
- Pharmacology & Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici, Largo Belloli, 11/A, 43122, Parma, Italy.
| | | | - Francesca Ruscitti
- Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali, Università di Parma, Parma, Italy
| | - Angela Sandri
- Dipartimento di Diagnostica e Salute Pubblica, Università di Verona, Verona, Italy
| | - Francesca Ravanetti
- Dipartimento di Scienze Medico Veterinarie, Università di Parma, Parma, Italy
| | - Gaetano Donofrio
- Dipartimento di Scienze Medico Veterinarie, Università di Parma, Parma, Italy
| | - Federico Boschi
- Dipartimento di Informatica, Università di Verona, Verona, Italy
| | - Gino Villetti
- Pharmacology & Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici, Largo Belloli, 11/A, 43122, Parma, Italy
| | - Claudio Sorio
- Dipartimento di Medicina, Università di Verona, Verona, Italy
| | - Barouk M Assael
- Centro Fibrosi Cistica, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Paola Melotti
- Centro Fibrosi Cistica, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Maria M Lleo
- Dipartimento di Diagnostica e Salute Pubblica, Università di Verona, Verona, Italy
| |
Collapse
|
6
|
Stellari F, Bergamini G, Sandri A, Donofrio G, Sorio C, Ruscitti F, Villetti G, Assael BM, Melotti P, Lleo MM. In vivo imaging of the lung inflammatory response to Pseudomonas aeruginosa and its modulation by azithromycin. J Transl Med 2015; 13:251. [PMID: 26239109 PMCID: PMC4522964 DOI: 10.1186/s12967-015-0615-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Accepted: 07/21/2015] [Indexed: 01/08/2023] Open
Abstract
Background Chronic inflammation of the airways is a central component in lung diseases and is frequently associated with bacterial infections. Monitoring the pro-inflammatory capability of bacterial virulence factors in vivo is challenging and usually requires invasive methods. Methods Lung inflammation was induced using the culture supernatants from two Pseudomonas aeruginosa clinical strains, VR1 and VR2, isolated from patients affected by cystic fibrosis and showing different phenotypes in terms of motility, colony characteristics and biofilm production as well as pyoverdine and pyocyanine release. More interesting, the strains differ also for the presence in supernatants of metalloproteases, a family of virulence factors with known pro-inflammatory activity. We have evaluated the benefit of using a mouse model, transiently expressing the luciferase reporter gene under the control of an heterologous IL-8 bovine promoter, to detect and monitoring lung inflammation. Results In vivo imaging indicated that VR1 strain, releasing in its culture supernatant metalloproteases and other virulence factors, induced lung inflammation while the VR2 strain presented with a severely reduced pro-inflammatory activity. The bioluminescence signal was detectable from 4 to 48 h after supernatant instillation. The animal model was also used to test the anti-inflammatory activity of azithromycin (AZM), an antibiotic with demonstrated inhibitory effect on the synthesis of bacterial exoproducts. The inflammation signal in mice was in fact significantly reduced when bacteria grew in the presence of a sub-lethal dose of AZM causing inhibition of the synthesis of metalloproteases and other bacterial elements. The in vivo data were further supported by quantification of immune cells and cytokine expression in mouse broncho-alveolar lavage samples. Conclusions This experimental animal model is based on the transient transduction of the bovine IL-8 promoter, a gene representing a major player during inflammation, essential for leukocytes recruitment to the inflamed tissue. It appears to be an appropriate molecular read-out for monitoring the activation of inflammatory pathways caused by bacterial virulence factors. The data presented indicate that the model is suitable to functionally monitor in real time the lung inflammatory response facilitating the identification of bacterial factors with pro-inflammatory activity and the evaluation of the anti-inflammatory activity of old and new molecules for therapeutic use.
Collapse
Affiliation(s)
- Fabio Stellari
- Pharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A. Parma, Largo Belloli, 11/A, 43122, Parma, Italy.
| | - Gabriella Bergamini
- Dipartimento di Patologia e Diagnostica, Università di Verona, Verona, Italy.
| | - Angela Sandri
- Dipartimento di Patologia e Diagnostica, Università di Verona, Verona, Italy.
| | - Gaetano Donofrio
- Dipartimento di Scienze Medico Veterinarie, Università di Parma, Parma, Italy.
| | - Claudio Sorio
- Dipartimento di Patologia e Diagnostica, Università di Verona, Verona, Italy.
| | - Francesca Ruscitti
- Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali, Università di Parma, Parma, Italy.
| | - Gino Villetti
- Pharmacology and Toxicology Department Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A. Parma, Largo Belloli, 11/A, 43122, Parma, Italy.
| | - Barouk M Assael
- Centro Regionale Fibrosi Cistica, AOUI Verona, Verona, Italy.
| | - Paola Melotti
- Centro Regionale Fibrosi Cistica, AOUI Verona, Verona, Italy.
| | - Maria M Lleo
- Dipartimento di Patologia e Diagnostica, Università di Verona, Verona, Italy.
| |
Collapse
|